Aktienanalyse zu ProMIS Neurosciences Inc (PMN)PMNProMIS Neurosciences Inc

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

ProMIS Neurosciences Inc (PMN) appears to be a good buy right now due to its promising clinical trial results for PMN310, which showed a favorable safety profile and significant declines in disease-relevant biomarkers. The current price is $13.79, and analysts have raised their price targets significantly, with Guggenheim setting a target of $69, suggesting a potential upside of over 400%. Additionally, the stock has seen a year-to-date change of +93.20%, indicating strong momentum. However, the company has reported negative net income in recent quarters, with a loss of $11,729,656 in Q2 2026, which remains a risk for investors.